Journal of innate immunity · 2026
The Small Ubiquitin-Like Modifier SUMO-3 Acts as a Neutrophil Chemoattractant via the Chemokine Receptors CXCR1 and CXCR2.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giblin Sean P, Moiseanu Vlad Razvan, Carrington Christina Josephine, Naing Audrey, Watkins Killian, Tsuchiya Tomoko, Kanegasaki Shiro, Pease James Edward
Аннотация
INTRODUCTION: Small ubiquitin-like modifiers (SUMOs) are small peptides conjugated to proteins during post-translational modification, which have been reported to modulate several aspects of the immune system, notably in autoimmune disorders.
METHODS: We used a SUMO-based bacterial expression system to create a recombinant protein putatively expressed by Toxocara canis, which we hypothesised might antagonise responses via the chemokine receptor CXCR1.
RESULTS: Although our recombinant T. canis protein was devoid of antagonist activity, we serendipitously observed that recombinant SUMO-3 protein had chemotactic activity for CXCR1 transfectants. Further study found that SUMO-3 acted as a full agonist of CXCR1 and the closely related receptor CXCR2, the latter responses ablated by a CXCR2 antagonist. SUMO-3 showed similar efficacy at both receptors but reduced potency when compared to CXCL8, with chemotaxis observed at high nanomolar to micromolar concentrations. In receptor endocytosis assays, SUMO-3 induced internalisation of CXCR1 and CXCR2, with inferior potency and efficacy to CXCL8. Translating our findings to primary cells, a broad range of SUMO-3 concentration gradients were shown to induce the chemotaxis of human neutrophils. Finally, SUMO-3 was found to be released by necrotic cells into the extracellular milieu.
CONCLUSIONS: Collectively, our findings suggest that SUMO-3 can induce the chemotaxis of neutrophils via CXCR1 and CXCR2. We postulate that in vivo, release of SUMO-3 from necrotic cells may serve to recruit neutrophils, contributing to tissue homeostasis and the resolution of inflammation.
METHODS: We used a SUMO-based bacterial expression system to create a recombinant protein putatively expressed by Toxocara canis, which we hypothesised might antagonise responses via the chemokine receptor CXCR1.
RESULTS: Although our recombinant T. canis protein was devoid of antagonist activity, we serendipitously observed that recombinant SUMO-3 protein had chemotactic activity for CXCR1 transfectants. Further study found that SUMO-3 acted as a full agonist of CXCR1 and the closely related receptor CXCR2, the latter responses ablated by a CXCR2 antagonist. SUMO-3 showed similar efficacy at both receptors but reduced potency when compared to CXCL8, with chemotaxis observed at high nanomolar to micromolar concentrations. In receptor endocytosis assays, SUMO-3 induced internalisation of CXCR1 and CXCR2, with inferior potency and efficacy to CXCL8. Translating our findings to primary cells, a broad range of SUMO-3 concentration gradients were shown to induce the chemotaxis of human neutrophils. Finally, SUMO-3 was found to be released by necrotic cells into the extracellular milieu.
CONCLUSIONS: Collectively, our findings suggest that SUMO-3 can induce the chemotaxis of neutrophils via CXCR1 and CXCR2. We postulate that in vivo, release of SUMO-3 from necrotic cells may serve to recruit neutrophils, contributing to tissue homeostasis and the resolution of inflammation.